2nd Circ. Nixes $1.3B Asthma Drug Suit V. AstraZeneca

Law360, New York (June 24, 2011, 5:02 PM EDT) -- The Second Circuit on Friday affirmed a win for AstraZeneca AB in a $1.3 billion suit accusing it of breaking a contract to develop a pediatric asthma drug for a San Diego pharmaceutical company.

Verus Pharmaceuticals Inc.'s contract with AstraZeneca merely required it to try to get regulatory approval in the U.S. for a drug called budesonide — it did not require the defendant to succeed, a three-judge panel ruled.

The plaintiff has for two years tried in vain to convince courts that AstraZeneca illegally dumped...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.